PetVivo Holdings, Inc.’s (NASDAQ: PETV) (NASDAQ: PETVW) ($PETV) interview with John Lai, CEO & President.


From the Nasdaq MarketSite studioPetVivo Holdings, Inc.’s (NASDAQ: PETV) (NASDAQ: PETVW) ($PETV) CEO / President, John Lai, talks with New to The Street’s TV Host Jane King. The Company is a biomedical device company that manufactures, commercializes, and licenses innovative medical devices and therapeutics for companion animals. The Company’s patented product, Spryng with OsteoCushion Technology, manages horses, dogs, and cats with osteoarthritis and joint-related issues. John informs viewers about a clinical study involving dogs inflicted with a torn cruciate (technically called a CCL or cranial cruciate ligament); it is like a human with a torn ACL (anterior cruciate ligament). The results to date are plentiful in the use of Spryng on dogs. A second study should confirm the results for successful treatment of CCL; expected results in October 2023. Currently, the only option for treatment without using Spryng is surgery. A veterinarian group is doing their study utilizing Spryng on canine hip dysplasia; they will present and demonstrate Spryng at an upcoming International Veterinary Academy of Pain Management conference. The Company looks forward to learning about their treatment outcome. John states that many studies are ongoing, and once data is available, the Company expects medical journals to publish results. Veterinarians are now discussing Spryng in continuing educational courses, giving information on how the product works as an alternative to treating osteoarthritis. These professional podium presentations about the Company and its products help educate end-users and potentially increase sales. About 90% of Spryng sales are for horses, but small animals like dogs and cats are a substantial growth segment. John expects the feline Spryng product to become available for veterinarians sometime in July 2023. Since the Company has strong animal data results, those results can help the Company with a future pursuit for FDA approval for Human use. Human use could take up to two years for regulatory approval. The interview will air on Newsmax TV, episode 454, April 1, 2023, at 3:30 PM ET and on the FOX Business Network, episode 455, April 3, 2023, at 10:30 PM PT. The on-screen QR code is available during the show; download or visit PetVivo Holdings, Inc. – & Spryng with OsteoCushion Technology –

To make sure you never miss a video from New to the Street, click here to subscribe:

Follow New to the Street on Twitter:

Follow New to the Street on Facebook:

Follow New to the Street on Instagram:

Follow New to the Street on Rumble:

About New to the Street:

Subscribe to our Mailing List: